NIH Won't Seize Patents To Cut Price Of Cancer Drug Xtandi

By Ryan Davis (March 21, 2023, 10:24 PM EDT) -- The National Institutes of Health on Tuesday rejected a petition urging the government to lower the price of the prostate cancer drug Xtandi by using so-called march-in rights to take control of the patents on the treatment marketed by Astellas Pharma Inc. and Pfizer Inc....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!